Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SimInSitu

Financiado

Cerrado

In silico Development and Clinical Trial Platform for Testing in situ Tissue En...

In silico Development and Clinical Trial Platform for Testing in situ Tissue Engineered Heart Valves SimInSitu is aiming to develop a sophisticated in-silico method to predict the short- and long-term behavior of in-situ tissue engineered heart valves by combing advanced tissue remodeling algorithms with a personalized virtual he... ver más

31/12/2024

4REALSIM SERVICES...

5M€

Presupuesto del proyecto: 5M€

Líder del proyecto

4REALSIM SERVICES BV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 15 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-12-31

SC1-DTH-06-2020: Accelerating the uptake of computer...

I+D

Cerrada hace 4 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

15 Participantes

4REALSIM SERVICES BV

1.23M€ | Lider

ABENGOA HIDRÓGENO

2.07M€ | Participante

ALSHARK & MARINE SOCIEDAD LI...

ALTUM INGENIERIA Y SERVICIOS...

282.62K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TAVI4Life A lifelong transcatheter aortic valve prosthesis 1M€ Cerrado

LIFEVALVE Living autologous heart valves for minimally invasive implan... 16M€ Cerrado

BIOMITRAL Engineering the mitral valve bioinspired control of structu... 2M€ Cerrado

ESPOIR European clinical study for the application of regenerative... 7M€ Cerrado

TECAS Towards Tissue Engineering Solutions for Cardiovascular Surg... 3M€ Cerrado

G-Valve Unraveling the mechanobiology of tissue growth in native and... 175K€ Cerrado

Duración del proyecto: 48 meses Fecha Inicio: 2020-12-03
Fecha Fin: 2024-12-31

Líder del proyecto

4REALSIM SERVICES BV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 5M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto SimInSitu is aiming to develop a sophisticated in-silico method to predict the short- and long-term behavior of in-situ tissue engineered heart valves by combing advanced tissue remodeling algorithms with a personalized virtual heart modelling approach. The method will be specifically developed to predict the complex transformation process of biodegradable heart valves from the initially synthetic scaffold into a fully remodeled & functional valve. This transformation process, named ETR for Endogenous Tissue Restoration, is the core technology for a new generation of very promising biodegradable vascular device currently developed by Xeltis. ETR makes the use of animal derived tissue, which is used in the majority of commercially available bioprosthetic heart valves, obsolete and avoids thereby durability related issues and potentially minimized the need for reoperations. Though, significant progress was made during the past years in developing ERT based devices, it remains very challenging, costly, time-consuming, and rich with obstacles. New knowledge can only be generated through a tedious trial & error process (requiring preclinical and clinical studies), since the restorative process cannot be replicated in an in-vitro environment. Advanced Computer Modelling & Simulation technologies have the potential to overcome this limitation by allowing to test new designs, modified scaffold compositions, or other applications in a virtual patient-specific environment – in-silico. SimInSitu will not only develop such a computer model, but will also verify and validate it thoroughly by making use of the extensive in-vitro and in-vivo data available and where necessary will generate new data to support the credibility of this in-silico method. The availability of this computer model could contribute significantly to an acceleration of especially the ETR-device development and accelerate their translation into the clinic and market.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores